Mark Laible

609 total citations
19 papers, 302 citations indexed

About

Mark Laible is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mark Laible has authored 19 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Mark Laible's work include Breast Cancer Treatment Studies (7 papers), Gene expression and cancer classification (6 papers) and HER2/EGFR in Cancer Research (5 papers). Mark Laible is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Gene expression and cancer classification (6 papers) and HER2/EGFR in Cancer Research (5 papers). Mark Laible collaborates with scholars based in Germany, Italy and Finland. Mark Laible's co-authors include Kornelia Schlombs, Ralph M. Wirtz, Sebastian Eidt, Uğur Şahin, Elke Veltrup, Peter Altevogt, Arndt Hartmann, Sotiris Lakis, Holger Sültmann and Johannes Breyer and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncotarget.

In The Last Decade

Mark Laible

16 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Laible Germany 10 131 111 101 77 66 19 302
Fatma Althoubaity Saudi Arabia 6 109 0.8× 86 0.8× 93 0.9× 41 0.5× 42 0.6× 10 253
Meng‐Zhong Liu China 6 122 0.9× 117 1.1× 66 0.7× 112 1.5× 92 1.4× 7 321
Vanessa de Luque Spain 9 135 1.0× 145 1.3× 164 1.6× 31 0.4× 50 0.8× 18 319
Quanzhou Peng China 11 232 1.8× 69 0.6× 121 1.2× 40 0.5× 72 1.1× 24 377
Héctor Aquiles Maldonado-Martínez Mexico 11 119 0.9× 106 1.0× 132 1.3× 33 0.4× 82 1.2× 23 296
Shi‐Xun Lu China 12 109 0.8× 120 1.1× 64 0.6× 53 0.7× 96 1.5× 21 277
Cigdem Ussakli United States 8 111 0.8× 155 1.4× 73 0.7× 70 0.9× 72 1.1× 10 308
Yae‐Eun Suh United Kingdom 9 188 1.4× 117 1.1× 139 1.4× 57 0.7× 98 1.5× 16 389
Junjie Li China 10 68 0.5× 99 0.9× 98 1.0× 30 0.4× 45 0.7× 28 234
Binhao Huang China 9 70 0.5× 135 1.2× 93 0.9× 72 0.9× 120 1.8× 22 305

Countries citing papers authored by Mark Laible

Since Specialization
Citations

This map shows the geographic impact of Mark Laible's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laible with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laible more than expected).

Fields of papers citing papers by Mark Laible

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Laible. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laible. The network helps show where Mark Laible may publish in the future.

Co-authorship network of co-authors of Mark Laible

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Laible. A scholar is included among the top collaborators of Mark Laible based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Laible. Mark Laible is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Schettini, Francesco, Silvana Saracchini, Serena Corsetti, et al.. (2024). Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study. The Breast. 76. 103753–103753. 1 indexed citations
3.
Laible, Mark, Stefan Wöll, Özlem Türeci, et al.. (2023). The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis. Journal of Translational Medicine. 21(1). 552–552. 17 indexed citations
4.
Bellezza, Guido, Martina Mandarano, Ivana Ferri, et al.. (2021). Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS ONE. 16(9). e0255580–e0255580. 8 indexed citations
5.
Saracchini, Silvana, Serena Corsetti, Ralph M. Wirtz, et al.. (2020). Abstract P1-10-23: Prediction of pathological complete response (pCR) upon neoadjuvant chemotherapy by MammaTyper® pCR score. Cancer Research. 80(4_Supplement). P1–10.
6.
7.
8.
Hartmann, Kerstin, Kornelia Schlombs, Mark Laible, et al.. (2018). Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagnostic Pathology. 13(1). 83–83. 3 indexed citations
9.
Gürtler, Claudia, et al.. (2018). Transferring a Quantitative Molecular Diagnostic Test to Multiple Real-Time Quantitative PCR Platforms. Journal of Molecular Diagnostics. 20(4). 398–414. 7 indexed citations
10.
Breyer, Johannes, Ralph M. Wirtz, Wolfgang Otto, et al.. (2017). Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 8(40). 67684–67695. 14 indexed citations
11.
Sinn, Hans‐Peter, Andreas Schneeweiß, Marius Keller, et al.. (2017). Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 17(1). 124–124. 63 indexed citations
12.
Laible, Mark, Yanis Tolstov, Stefan Duensing, et al.. (2017). TMPRSS2:ERGgene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells. Oncotarget. 8(15). 25115–25130. 22 indexed citations
13.
Wirtz, Ralph M., Harri Sihto, Jorma Isola, et al.. (2016). Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Research and Treatment. 157(3). 437–446. 28 indexed citations
14.
Breyer, Johannes, Wolfgang Otto, Ralph M. Wirtz, et al.. (2016). ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urologia Internationalis. 98(3). 282–289. 27 indexed citations
15.
16.
Breyer, Johannes, Ralph M. Wirtz, Mark Laible, et al.. (2016). ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 469(5). 547–552. 26 indexed citations
17.
Wirtz, Ralph M., Tilman T. Rau, Mark Laible, et al.. (2015). Abstract P5-10-13: Low influence of tumor cell content on mRNA expression levels of ESR, PGR, HER2 and KI67 when performing the MammaTyper® RT-PCR kit. Cancer Research. 75(9_Supplement). P5–10. 1 indexed citations
18.
Laible, Mark, Jan C. Brase, Stefan T. Börno, et al.. (2013). ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer. PLoS ONE. 8(3). e59976–e59976. 23 indexed citations
19.
Löbke, Christian, Mark Laible, Markus Ruschhaupt, et al.. (2008). Contact spotting of protein microarrays coupled with spike‐in of normalizer protein permits time‐resolved analysis of ERBB receptor signaling. PROTEOMICS. 8(8). 1586–1594. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fatma Althoubaity Breakdown of academic impact, for papers by Meng‐Zhong Liu Breakdown of academic impact, for papers by Vanessa de Luque Breakdown of academic impact, for papers by Quanzhou Peng Breakdown of academic impact, for papers by Héctor Aquiles Maldonado-Martínez Breakdown of academic impact, for papers by Shi‐Xun Lu Breakdown of academic impact, for papers by Cigdem Ussakli Breakdown of academic impact, for papers by Yae‐Eun Suh Breakdown of academic impact, for papers by Junjie Li Breakdown of academic impact, for papers by Binhao Huang
Rankless by CCL
2026